List view / Grid view

Issue 1 2013

Filter the results

 

article

Gene to drugs: can expression be the key to new discoveries?

25 February 2013 | By Esther P. Black, College of Pharmacy and Markey Cancer Center, University of Kentucky

Cancer treatment faces a conundrum: a growing lack of therapeutics with lasting effects. The low hanging fruit of the medicinal chemistry orchard seems to have been picked, and modification of existing anti-cancer therapeutics has produced only incremental rewards[1]. Thus, both pharmaceutical companies and academic researchers are left searching for new…

article

Industry Expert Panel

21 February 2013 | By

Welcome to European Pharmaceutical Review’s Industry Expert Panel. We have assembled a panel of authoritative voices from the pharmaceutical industry to speak on a wide range of issues that affect this industry, sharing their expertise and insight with our readers.

article

Applications of solid-state NMR spectroscopy to pharmaceuticals

21 February 2013 | By Eric Munson, Patrick DeLuca Endowed Professor in Pharmaceutical Technology, Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky

Solid-state NMR spectroscopy (SSNMR) has emerged as an extremely powerful analytical technique for the characterisation of pharmaceuticals[1-5]. Despite its capability, SSNMR is still not used ubiquitously in the pharmaceutical industry. Several factors contribute to this, including cost and analysis time, but two of the major reasons are understanding the full…

article

Extracellular microRNA: the promises for the diagnostics of multiple diseases

21 February 2013 | By Andrey Turchinovich and Barbara Burwinkel, German Cancer Research Center

This mini-review aims to summarise recent advances in the field of molecular diagnostic of diseases using extracellular circulating miRNA in biological fluids. We will also discuss obstacles in developing miRNAs as circulating biomarkers as well as the potential future of the field.

article

Getting to grips with drug resistance in the human protein kinase superfamily

21 February 2013 | By Patrick A Eyers, Department of Oncology, Sheffield Cancer Research Centre, University of Sheffield

Protein kinases represent a vast, partially untapped resource of drug targets for therapeutic intervention in human disease. The remarkable success of the tyrosine kinase inhibitor Imatinib, which is now the first-line therapy in Philadelphia-positive tyrosine kinase inhibitor Imatinibhas galvanised biomedical researchers in an attempt to repeat the landmark success of…

article

Improving the quantitation of live antigens used to produce rabbit generated serotype specific antiserum

21 February 2013 | By Michael J. Miller, President, Microbiology Consultants, LLC, Silvia Fragoeiro, Ananthi Ramachandran and Paul van Empel MSD Animal Health

This is the first paper in our continuing series on Rapid Microbiological Methods (RMM) that will appear in European Pharmaceutical Review during 2013. Flow cytometry represents one of a variety of viability-based RMM technologies that are currently available to the pharmaceutical industry. In flow cytometry, individual particles are counted as…

article

Practical Workshop – Biochemical Assays for Screening

21 February 2013 | By Sheraz Gul, Head of Biology at European ScreeningPort, Hamburg, Germany

Recent years have witnessed an expansion in the disciplines encompassing drug discovery outside the pharmaceutical industry. This is most notable with a significant number of universities worldwide that now host infrastructure such as compound libraries and automated screening centres[1-3]. An archetypal small molecule drug discovery project will aim to identify…

article

The evolution of the Contract Research Organisation and the future of the pharmaceutical industry

20 February 2013 | By , ,

This article discusses how the pharmaceutical industry can leverage its competencies in outsourcing to accelerate time to market, improve quality and increase innovation at all stages of the drug discovery and development process. The pharmaceutical industry is being battered by a perfect storm of not just one but three major…